Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program

References

• American Association for the Treatment of Opioid Dependence, Inc. Increasing access to medication to treat opioid addiction—increasing access for the treatment of opioid addiction with medications. New York, NY: AATOD, 2014.
   Google Scholar
• White W. Recovery management and recovery-oriented systems of care: scientific rationale and promising practices. Pittsburgh, PA: Northeast Addiction Technology Transfer Center, Great Lakes Addiction Technology Transfer Center, Philadelphia Department of Behavioral Health & Mental Retardation Services, 2008.
   Google Scholar
• White W, Torres L. Recovery-oriented methadone maintenance. Chicago, IL: Great Lakes Addiction Technology Transfer Center, Philadelphia Department of Behavioral Health and Mental Retardation Services and Northeast Addiction Technology Transfer Center, 2010.
   Google Scholar
• Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R. The SUMMIT Trial: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat 2010; 39:340–52.
   PubMed Web of Science ®Google Scholar
• Potter JS, Marino EN, Hillhouse MP, et al. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs 2013; 74:605–13.
   PubMed Web of Science ®Google Scholar
• Hser YI, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2013; 109:79–87.
   PubMed Web of Science ®Google Scholar
• Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009; 104:1193–200.
   PubMed Web of Science ®Google Scholar
• Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat 2009; 37:426–30.
   PubMed Web of Science ®Google Scholar
• Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med 2005; 20:1038–41.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2–5 years. Am J Addict 2008; 17:116–20.
   PubMed Web of Science ®Google Scholar
• Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med 2011; 171:425–31.
   PubMed Web of Science ®Google Scholar
• Haddad MS, Zelenev A, Altice FL. Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes. Drug Alcohol Depend 2013; 131:127–35.
   PubMed Web of Science ®Google Scholar
• Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 2007; 5:146–50.
   PubMed Web of Science ®Google Scholar
• Parran TV, Adelman CA, Merkin B, et al. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend 2010; 106:56–60.
   PubMed Web of Science ®Google Scholar
• Magura S, Lee SJ, Salsitz EA, et al. Outcomes of buprenorphine maintenance in office-based practice. J Addict Dis 2007; 26:13–23.
   PubMed Web of Science ®Google Scholar
• Moore BA, Fiellin DA, Barry DT, et al. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med 2007; 22:527–30.
   PubMed Web of Science ®Google Scholar
• Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized control trial. JAMA 2008; 300:2003–11.
   PubMed Web of Science ®Google Scholar
• Cornish R, Macleod J, Strang J, Vickerman P, Hickman, M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010; 341:c5475.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns, L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend 2009; 105:9–15.
   PubMed Web of Science ®Google Scholar
• Schwartz RP, Gryczynski J, O'Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. Am J Public Health 2013; 103:917–22.
   PubMed Web of Science ®Google Scholar
• Bell J, Trinh L, Butler B, Randall D, Rubin, G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009; 104:1193–200.
   PubMed Web of Science ®Google Scholar
• Woody GE, Bruce D, Korthuis PT, et al. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J. Acquir. Immune Defic. Syndr 2014; 66:288–93.
   PubMed Web of Science ®Google Scholar
• Edelman EJ, Chantarat T, Caffrey S. The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients. Drug Alcohol Depend 2014; 139:79–85.
   PubMed Web of Science ®Google Scholar
• Roux P, Carrieri MP, Villes, V. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction 2008; 103:1828–36.
   PubMed Web of Science ®Google Scholar
• White WL, Campbell MD, Spencer RD, Hoffman HA, Crissman B, DuPont RL. Patterns of abstinence or continued drug use among methadone maintenance patients and their relation to treatment retention. J Psychoactive Drugs 2014; 46:114–22.
   PubMed Web of Science ®Google Scholar